Here, we randomized 53 patients hospitalized with coronavirus disease 2019 (COVID-19) to hydroxychloroquine therapy (at a dose of 400 mg twice daily for seven days) in addition to standard care or standard care alone (ClinicalTrials.gov Identifier, NCT04316377). All severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients 18 years of age or older were eligible for study inclusion if they had moderately severe COVID-19 at admission. Treatment with hydroxychloroquine did not result in a significantly greater rate of decline in SARS-CoV-2 oropharyngeal viral load compared to standard care alone during the first five days. Our results suggest no important antiviral effect of hydroxychloroquine in humans infected with SARS-CoV-2. The use of hydroxychloroquine therapy for the treatment of Covid-19 is controversial. In this study, Lyngbakken and colleagues present a randomized controlled trial and show that the drug has no antiviral effects in humans infected with SARS-CoV-2.
【저자키워드】 viral infection, Randomized controlled trials, Therapeutics, 【초록키워드】 COVID-19, Randomized controlled trial, Treatment, coronavirus disease, SARS-CoV-2, Coronavirus disease 2019, coronavirus, therapy, Hydroxychloroquine, Human, antiviral effects, drug, Antiviral effect, Randomized, Viral, Viral load, age, Oropharyngeal, respiratory, Admission, dose, acute respiratory syndrome, Older, treatment of COVID-19, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, standard care, Identifier, study inclusion, hydroxychloroquine therapy, moderately severe COVID-19, SARS-CoV-2 oropharyngeal viral load, FIVE, Seven, greater, significantly, addition, positive patient, eligible, infected with SARS-CoV-2, patients hospitalized, use of hydroxychloroquine, 【제목키워드】 Coronavirus disease 2019, Efficacy, Hydroxychloroquine, Viral, viral kinetics, Pragmatic, lack,